Clinical association of localized intraventricular conduction defect

A prospective study was organized to clarify the clinical association of localized intraventricular conductions [LIVCD]. Fifty patients with symptoms suggesting cardiac origin were studied and subjected to chest X-ray, E.C.G, holter ambulatory monitoring, and treadmill test. The results showed that LIVCD seems to be acquired. Ischemic heart disease constituted the most frequent associated condition [42%]. Hypertension not associated with ischemia constituted the next frequent condition [30%]. Obesity and diabetes mellitus account for [10% and 8%], respectively. No definite association could be found in the remaining 10% of cases, a finding which might be related to other factors e.g. sclerodegenerative affection, myocaraditis, cardiomyopathy. Indeed patients with LIVCD are in need for long-term follow up to monitor the progression of this condition to other types of intraventricular conduction defects

use of arteriolar vasodilator in the management of advanced congestive heart failure

This study reports on therapeutic effect of hydralazine in the management of advanced congestive heart failure [ACHF] in Iraq. One hundred patients, with ACHF [class 4 of NYHA classification] were studied pressure, and the physical fitness for walking were taken as a follow up indicator for beneficial effect. Three months follow up after treatment showed that 50% of patients were stepped up to class 3 of NYHA. Six months follow up showed that 52% were in a good condition, and were satisfy the class 2 of NYHA. One year later 68% of the total patients were survived and they were stepped up, at least, one class of NYHA. Two years follow up showed that 60% of total patients were still surviving with 42% of them satisfy the criteria of class 2 of NYHA. The remaining patients of the total surviving [i.e. 18%] were in class 3 of NYHA. The mortality rate was 10%, 15% and 25% after 6 months, one year, and two years of treatment respectively. Incidence of sudden death was 5% among all patients through the 2 years period of study. As a result of the improvement in clinical states and reduction in mortality, hydralazine would be recommended to be used in the management of congestive heart failure